A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania

Inclusion criteria: * Has a confirmed diagnosis of moderate-to-severe plaque psoriasis * Participant must sign an informed consent form allowing source data verification in accordance with local requirements * Is able to read, understand, and complete the patient reported outcomes (PRO) instruments in local language and comply with completion of all PRO instruments * No previous exposure to biological treatment, including guselkumab (bio-naive patient) * Intended for the treatment with guselkumab according to the approved indication Exclusion criteria: * Meets any of the contraindications according to the latest version of the locally approved summary of product characteristics (SmPC) * Is pregnant or lactating * Current or recent (in the last 30 days prior to first SC dose of guselkumab) participation in any interventional study with investigational product. * Currently enrolled in another observational study sponsored or managed by a Johnson \& Johnson company